Tristețe persistentă, lipsa energiei și a motivației.
106 articoleA neuroimaging study examined how transdermal estradiol affects brain connectivity patterns in perimenopausal women with depression versus controls over three weeks. Results showed estradiol induced specific changes in connectivity between reward/emotion processing regions, suggesting a neural mechanism for hormone therapy's mood benefits in perimenopausal depression.
This review examines emerging pharmacological targets and novel antidepressant compounds for treating major depressive disorder, focusing on their mechanisms of action and supporting evidence. While conventional antidepressants remain primary treatment, ongoing research explores new compounds showing promising results for treatment-resistant depression.
This retrospective study examined psychiatric readmission rates for adults with major depressive disorder based on which antidepressant medication they received at hospital discharge. Patients discharged on sertraline showed significantly lower 30-day readmission rates compared to other antidepressant treatments, though the small sample size limits generalizability.
This case report describes a 44-year-old man with major depressive disorder and psychotic features who experienced Cotard's delusion (false belief that parts of his body were decaying or that he was dead). The patient showed limited response to various antidepressant-antipsychotic combinations but achieved substantial improvement with venlafaxine monotherapy, highlighting the need for further research into optimal pharmacological treatments for this rare condition.
This study examined 1,243 adults with major depressive disorder to understand how hypomanic symptoms affect treatment response and suicidal ideation remission. Patients with hypomanic symptoms showed poorer treatment response and higher suicide ideation, while certain psychiatric medications showed benefit in improving outcomes.
Depression and anxiety are significantly more common in cirrhosis patients than the general population, with prevalence increasing substantially over the past decade, and both conditions negatively impact quality of life and treatment outcomes. Management involves screening, pharmacological treatment with dose-adjusted antidepressants, psychotherapy, and multidisciplinary care approaches tailored to the patient's hepatic function.
This review examines the relationship between REM sleep abnormalities and psychiatric disorders, particularly major depression, following 70 years of research since REM sleep's 1953 discovery. Key findings link depression to reduced REM latency, increased REM volume, and higher REM density, with implications for understanding emotional processing and developing improved treatments.
This work examines the relationship between depression, sexual dysfunction, and antidepressant medications, exploring how these factors interact clinically. It addresses both the depressive condition itself and medication-related adverse effects on sexual function.
A clinical case report documents two patients with treatment-resistant depression who initially responded to intranasal esketamine but subsequently experienced rapid deterioration in depressive symptoms and increased suicidal ideation, which improved upon discontinuation. The authors use validated psychiatric rating scales to assess outcomes and acknowledge that the mechanism underlying these paradoxical adverse reactions remains unclear.
This review examines cariprazine, a D2/D3 partial agonist atypical antipsychotic, as a potential adjunctive treatment for major depressive disorder patients with inadequate response to standard antidepressants. Preliminary evidence suggests cariprazine may improve motivation, anhedonia, and cognitive symptoms, though its effects on anxiety, agitation, and psychomotor symptoms remain uncertain.
A retrospective analysis of 15 years of electronic health records from 13,607 patients with major depressive disorder found that 11.8% later converted to bipolar disorder. Using Cox regression modeling, researchers identified key predictive factors including severity of initial depression, psychosis, hospitalization, family history of bipolar disorder, female gender, and suicidality derived from clinical notes.
Anhedonia, the inability to experience pleasure, is a challenging symptom in major depressive disorder and schizophrenia involving dopaminergic system dysfunction. Treatment approaches include combination pharmacotherapy (glutamatergic agents, KOR antagonists, KCNQ activators), neurostimulation, and psychotherapy, with accurate component identification and reward system understanding being key to selecting effective interventions.
This narrative synthesis systematically examines peer-reviewed research on how prolonged and intermittent fasting affect mood, cognition, stress physiology, and psychiatric symptoms, covering both secular and religious fasting practices from 2010-2025. The review evaluates clinical trials and observational studies while critically assessing study quality and vulnerability factors, acknowledging that psychoneurobiological psychiatric consequences of fasting remain incompletely characterized despite documented metabolic benefits.
This study measured blood MMP-9 levels in 186 depressed hospital patients (92 with recent suicide attempts, 94 without) and 79 non-psychiatric controls, finding significantly elevated MMP-9 in the recent attempt group compared to both other groups. Results suggest MMP-9 may be a biological marker associated with suicide risk in major depressive disorder.
This review evaluates psilocybin's therapeutic potential for major depressive disorder by analyzing clinical studies from 2014-2024, examining its efficacy, safety, and mechanisms of action through serotonin receptor activity and neuroplasticity enhancement. The research highlights promising rapid and sustained symptom relief but emphasizes the need for larger studies, regulatory reform, and long-term safety data to fully establish psilocybin-assisted therapy as a viable treatment option.
This systematic review evaluates the association between GLP-1 receptor agonists (medications used for diabetes and weight loss) and psychiatric manifestations including depression, suicidality, eating disorders, and substance use disorders. Evidence suggests modest antidepressant effects and potential therapeutic benefit in reward-regulation disorders, though concerns about suicidality remain unresolved and research is limited by small sample sizes and underrepresentation of people with psychiatric comorbidities.
This review examines immune-driven depression, a major depressive disorder subtype characterized by low-grade inflammation and metabolic disturbances, which shows distinct treatment responses and worse clinical outcomes. Recent evidence includes sex-specific inflammatory associations, novel interventions like GLP-1 agonists and low-dose interleukin-2, and biomarker-guided patient stratification using markers such as hsCRP and motivational anhedonia.
A case study of a patient initially diagnosed with postpartum depression who developed hypomanic symptoms after antidepressant treatment, leading to correct diagnosis of bipolar II disorder. Integrated treatment combining mood-stabilizing medication, CBT, DBT, psychoeducation, and lifestyle interventions resulted in sustained mood stabilization and improved functioning.